Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Chehrazi-Raffle on the Safety of Second-Line Tivozanib With/Without Nivolumab in RCC

June 13th 2025

Alexander Chehrazi-Raffle, MD, details safety data and the clinical implications of an analysis of second-line tivozanib for patients with metastatic RCC.

Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL

June 13th 2025

Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.

Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL

June 13th 2025

Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.

Dr Graham on Advancements in the Management of Ovarian Cancer

June 13th 2025

Deena M. Atieh Graham, MD, discusses notable shifts within the ovarian cancer landscape leading to better patient outcomes.

Dr Benjamin on Using Real-World Data to Bridge Knowledge Gaps in Urothelial Cancer Care

June 12th 2025

David J. Benjamin, MD, expands on real-world studies to help contextualize clinical trial data and inform treatment decisions in urothelial cancer.

Dr Hayne on Mitomycin/BCG as an Alternative to BCG Alone in Non–Muscle-Invasive Bladder Cancer

June 12th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses the use of mitomycin plus BCG as a potential alternative to BCG alone in non–muscle-invasive bladder cancer.

MVdeltaC Receives FDA Orphan Drug Designation in Pleural Mesothelioma

June 12th 2025

The oncolytic virus candidate MVdeltaC has received FDA orphan drug designation for the treatment of patients with pleural mesothelioma.

FDA Grants Fast Track Designation to CHM CDH17 for Gastroenteropancreatic NETs

June 12th 2025

CHM CDH17 has received fast track designation from the FDA for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Dr Sabari on c-MET as a Potential Biomarker of Response in EGFR Wild-Type NSCLC

June 11th 2025

Joshua Sabari, MD, explains the rationale behind targeting c-MET in nonsquamous EGFR wild-type advanced NSCLC.

DESTINY-Breast09 and Ongoing Trials Underscore Shifting ADC Landscape in HER2+ Breast Cancer

June 11th 2025

Hope S. Rugo, MD, discusses key considerations and unanswered questions arising from the DESTINY-Breast09 trial in HER2-positive breast cancer.

Dr Kalinsky on Evolving Roles for the CLEOPATRA and DESTINY-Breast09 Regimens in HER2+ Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses potential new roles for the CLEOPATRA and DESTINY-Breast09 regimens in the HER2-positive breast cancer paradigm.

SERENA-6 Introduces Potential New Paradigm of Early ESR1 Mutation Detection to Delay Progression in HR+ Breast Cancer

June 9th 2025

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

T-DXd Plus Pertuzumab Could Disrupt First-Line SOC in HER2+ Metastatic Breast Cancer

June 6th 2025

Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Rugo on Research Needed to Clarify the Role of T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Rugo on Ongoing ADC Investigations Set to Shift Practice in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Dr Sammons on the Significance of DESTINY-Breast09 for the HER2+ Breast Cancer Treatment Paradigm

June 5th 2025

Sarah Sammons, MD, contextualizes the importance of T-DXd plus pertuzumab within the evolving ADC arsenal for HER2-positive breast cancer.

Dr Haas on 5-Year Outcomes With Adjuvant Pembrolizumab in ccRCC

June 5th 2025

Naomi B. Haas, MD, shares 5-year follow-up data with adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

China’s NMPA Approves Cadonilimab Plus Chemo With/Without Bevacizumab in Cervical Cancer

June 5th 2025

Cadonilimab plus chemotherapy with or without bevacizumab has received NMPA approval for first-line recurrent or metastatic cervical cancer.

China’s NMPA Accepts NDA for Sintilimab Plus Fruquintinib in Second-Line Advanced/Metastatic RCC

June 5th 2025

A new drug application seeking the Chinese approval of sintilimab plus fruquintinib in second-line advanced/metastatic RCC has been accepted by the NMPA

Single-Agent Tivozanib Shows Activity in Metastatic RCC After Contemporary Frontline Therapy

June 4th 2025

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.